P275 INFLUENCE OF INFLAMMATION AND TREATMENT ON ILEAL AND COLONIC ANTIMICROBIAL DEFENSIN EXPRESSION IN ACTIVE CROHN'S DISEASE
Irmgard Kübler(Robert Bosch Hospital), Jan Wehkamp(Robert Bosch Hospital), Eduard F. Stange(John Radcliffe Hospital), Michael Gersemann(Robert Bosch Hospital), Johan Burisch(University of Copenhagen), Klaus Fellermann(Apple (Israel)), K Herrlinger(Robert Bosch Hospital), Maureen J. Koslowski(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Guangshun Wang(University of Nebraska Medical Center)
Cited by 0
Related Papers
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
|Journal of Crohn s and Colitis|2019|1.4k
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment
|Journal of Crohn s and Colitis|2019|1.1k
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
|Journal of Crohn s and Colitis|2021|1.1k
Reduced Paneth cell α-defensins in ileal Crohn's disease
|Proceedings of the National Academy of Sciences|2005|969